Landmark overall survival of 89% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibody
- DOI
- 10.1016/j.ejcskn.2026.100850
- Published
- 2026
- Container
- EJC Skin Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejcskn.2026.100850,
title = {Landmark overall survival of 89\% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibody},
author = {A. Mangla and I. Mehmi and J.E. Selfridge and M. Taylor and C. Albany and V. Kwatra and J. Thomas and S. Hu-Lieskovan and K. Chen and J. Llorin-Sangalang and K. Aysola and O. Hamid},
year = {2026},
journal = {EJC Skin Cancer},
doi = {10.1016/j.ejcskn.2026.100850},
url = {https://doi.org/10.1016/j.ejcskn.2026.100850}
}RIS
TY - JOUR TI - Landmark overall survival of 89% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibody AU - A. Mangla AU - I. Mehmi AU - J.E. Selfridge AU - M. Taylor AU - C. Albany AU - V. Kwatra AU - J. Thomas AU - S. Hu-Lieskovan AU - K. Chen AU - J. Llorin-Sangalang AU - K. Aysola AU - O. Hamid PY - 2026 JO - EJC Skin Cancer DO - 10.1016/j.ejcskn.2026.100850 UR - https://doi.org/10.1016/j.ejcskn.2026.100850 ER -
APA
Mangla, A., Mehmi, I., Selfridge, J., Taylor, M., Albany, C., Kwatra, V., Thomas, J., Hu-Lieskovan, S., Chen, K., Llorin-Sangalang, J., Aysola, K., & Hamid, O. (2026). Landmark overall survival of 89% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibody. EJC Skin Cancer. https://doi.org/10.1016/j.ejcskn.2026.100850
Source records
- crossref · retrieved 2026-09-26T21:47:05.082Z